Direct Oral Anticoagulants and Acute Ischemic Stroke Direct oral anticoagulants (DOAC), the
factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and the direct thrombin inhibitor …

Direct Oral Anticoagulants and Acute Ischemic Stroke Direct oral anticoagulants (DOAC), the
factor Xa inhibitors rivaroxaban, apixaban, edoxaban, and the direct thrombin inhibitor …

With increasing use of direct oral anticoagulants (DOACs), a common conundrum in acute
stroke is whether to give thrombolysis to a person who is otherwise eligible but is taking …

Nearly 20% of patients with acute ischemic stroke (AIS) are undergoing direct oral
anticoagulant (DOAC) treatment at the time of their stroke. 1 Common indications for DOACs …

Abstract Purpose of Review Direct oral anticoagulants (DOACs: the factor Xa inhibitors
rivaroxaban, apixaban, and edoxaban and the direct thrombin inhibitor dabigatran) are the …

A rapidly increasing proportionof patients with acute ischemic stroke who are otherwise
eligible for thrombolysis are excluded from this treatment because of possible or known …

Direct oral anticoagulants (DOACs) have emerged as primary therapeutic option for stroke
prevention in patients with atrial fibrillation. However, patients may have ischaemic stroke …

Intravenousthrombolytictherapywithrecombi…-minogen activator (alteplase) is the
cornerstone of acute ischemic stroke reperfusion therapy and is associated with significant …

Background Direct-acting oral anticoagulants (DOACs), including apixaban, rivaroxaban,
edoxaban, and dabigatran, are widely used for various indications and considered first-line …

Introduction: The objective of our study was to identify the underlying causes of acute
ischemic strokes (AIS) in patients prescribed direct oral anticoagulants (DOACs). Methods …